Apr 3, 2024 · Parkinson’s disease is a common and debilitating disorder. The best-known features are resting tremor, rigidity, and slowness, but recently a fuller picture of the associated complications has...

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain. Neuroreport. 2016;27:384–391. doi: 10.1097/WNR.0000000000000548.

Jan 15, 2025 · Promising preliminary data have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have a neuroprotective effect against PD, potentially slowing the progression of PD and helping patients maintain their motor function.

Apr 3, 2024 · Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease.

Nov 5, 2024 · The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01

Jan 1, 2025 · GLP-1 receptor agonists may decrease neuroinflammation by reducing microglia activation in Parkinson's Disease. This study evaluates the efficacy of GLP-1 receptor agonists in improving Parkinson's Disease symptoms.

Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson’s Disease (PD).

Dec 10, 2024 · Glucose metabolism and energy metabolism disorders also play an important role in the pathogenesis of PD. This review investigates the neuroprotective mechanisms of glucagon-like peptide-1 (GLP-1) and its receptor agonists, offering novel insights into potential therapeutic strategies for PD.

Jul 23, 2020 · Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.

Mar 29, 2024 · Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD.